Blockade of the Renin-angiotensin-aldosterone System in Patients With ARVD

Who May Qualify: - \>18years old - Diagnosis of ARVD based on Task Force criteria. Two major criteria: 1 morphologic and one rhythmic or 1 major and 2 minor criteria established by the European Society of Cardiology/International Society and Federation of Cardiology. - Left Ventricular Ejection Fraction \>40% - Written willing to sign a consent form. Who Should NOT Join This Trial: - Patients under judicial protection. - Female patient who is pregnant or lactating, or is of child bearing potential (defined as a sexually mature woman not surgically sterilized or not post-menopausal for at least 24 consecutive months if ≤ 55 years or 12 months if \> 55 years) and who did not agree to use highly effective methods of birth control throughout the study. - No health insurance. - Right heart failure patient (RV volume\>150ml). - Spironolactone contraindication: anuria, hyperkalemia (K+\>5 mmol/l), renal failure (DFGCréat\>22 mL/min/1,73 m2), end-stage liver failure, Addison's Disease, hypersensitivity to spironolactone or to any of the excipients (patients with galactose intolerance, lapp lactase deficiency or glucose or galactose malabsorption syndrome), association with eplerenone, association with other hyperkalemic diuretics, association with potassium salts, not recommended in cirrhotic patients (natraemia\<125 mmol/l) or in patients likely to present an acidosis. - Mandatory indication for a combination of ACE inhibitor and sartan or renin inhibitor (each authorized separately). - Acute phase of systemic disease. - Uncompensated hypothyroidism. - Acute hyperthyroidism. - Normal right ventricular volume. - Heart transplantation. - Swallowing disorders. - Participation in any other interventional clinical investigation that may have an impact on our study. Always talk to your doctor about whether this trial is right for you.